Neuropsych Dis Treat
-
Neuropsych Dis Treat · Jan 2013
Celiac plexus neurolysis for the treatment of upper abdominal cancer pain.
Optimal treatment of oncologic pain is a challenge to all professionals who deal with cancer and its complications. The management of upper abdominal pain is usually difficult and it is often refractory to conservative therapies. ⋯ In this study, the importance of CPN is reviewed by a retrospective study of 74 patients with pain due to upper abdominal cancer. Almost all cases evaluated (94.6%) had an excellent result after CPN and the majority of side effects were transitory.
-
Neuropsych Dis Treat · Jan 2013
Effectiveness and safety of Nintendo Wii Fit Plus™ training in children with migraine without aura: a preliminary study.
Migraine without aura (MoA) is a painful syndrome, particularly in childhood; it is often accompanied by severe impairments, including emotional dysfunction, absenteeism from school, and poor academic performance, as well as issues relating to poor cognitive function, sleep habits, and motor coordination. ⋯ Our study reported the positive effects of the Nintendo Wii Fit Plus™ system as a rehabilitative device for the visuomotor and balance skills impairments among children affected by MoA, even if further research and longer follow-up are needed.
-
Neuropsych Dis Treat · Jan 2013
Profile of lacosamide and its role in the long-term treatment of epilepsy: a perspective from the updated NICE guideline.
The goal of antiepileptic treatment is to achieve seizure freedom or seizure control. The aim of this paper is to review the evidence for the use of lacosamide for adjunctive treatment of refractory focal seizures with or without secondary generalization, within the scope of the 2012 update of the Clinical Guideline published by the National Institute for Health and Clinical Excellence (NICE). ⋯ Lacosamide was included as part of the recommended AEDS to be used in tertiary epilepsy centers. The evidence review showed that more participants who received lacosamide as an adjunctive treatment had at least a 50% reduction in seizure frequency compared with those taking placebo. However, more participants on lacosamide were found to experience adverse events and withdrawal from treatment compared with those on placebo. The cost-effectiveness analysis showed that compared with placebo, the benefits gained from adjunctive lacosamide were modest and uncertain, whereas the costs were significantly high. Compared with other AEDs licensed for adjunctive therapy in focal seizures, lacosamide was associated with fewer quality-adjusted life years and higher costs. Therefore, the Guideline Development Group noted that the balance of benefit and harm needs to be carefully monitored in all patients.
-
Neuropsych Dis Treat · Jan 2013
A validation study of the Chinese-Cantonese Addenbrooke's Cognitive Examination Revised (C-ACER).
There is no valid instrument for multidomain cognitive assessment to aid the detection of mild cognitive impairment (MCI) and mild dementia in Hong Kong. This study aimed to validate the Cantonese Addenbrooke's Cognitive Examination Revised (C-ACER) in the identification of MCI and dementia. ⋯ C-ACER is a sensitive and specific bedside test to assess a broad spectrum of cognitive abilities, and to detect MCI and dementia of different severity. It can be used and interpreted with ease, without the need to adjust for education level in persons aged 60 or above.
-
Neuropsych Dis Treat · Jan 2013
Risk-benefit considerations in the treatment of relapsing-remitting multiple sclerosis.
Multiple sclerosis (MS) is a chronic demyelinating disease of the central nervous system and mainly affects young adults. Its natural history has changed in recent years with the advent of disease-modifying drugs, which have been available since the early 1990s. The increasing number of first-line and second-line treatment options, together with the variable course of the disease and patient lifestyles and expectations, makes the therapeutic decision a real challenge. ⋯ There is no single best treatment strategy, but therapy has to be tailored to the patient. This is a time-consuming task, rich in complexity, and influenced by the attitude towards risk on the parts of both the patient and the clinical team. The broader the MS drug market becomes, the harder it will be for the clinician to help the patient decide which therapeutic strategy to opt for.